Ticagrelor

證據等級: L5

預測適應症: 10 個

Ticagrelor: From Acute Coronary Syndrome to Intracranial Arteriosclerosis

One-Sentence Summary

Ticagrelor is a potent oral P2Y12 receptor antagonist originally used to reduce cardiovascular events in patients with Acute Coronary Syndrome (ACS) and ischemic cardiovascular disease. The TxGNN model predicts it may be effective for Intracranial Arteriosclerosis, with 11 clinical trials and 3 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Acute Coronary Syndrome / Ischemic Cardiovascular Disease
Predicted New Indication	Intracranial Arteriosclerosis
TxGNN Prediction Score	99.97%
Evidence Level	L1
Italy Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Ticagrelor is a direct-acting, reversibly binding P2Y12 receptor antagonist. Unlike older thienopyridines, it does not require hepatic bioactivation, providing faster onset and more consistent platelet inhibition. Its efficacy in reducing major cardiovascular events (cardiovascular death, MI, stroke) in ACS patients has been established through landmark large-scale RCTs including PLATO. Importantly, Ticagrelor also inhibits ENT-1 (equilibrative nucleoside transporter 1) on erythrocytes and platelets, increasing local adenosine concentrations — contributing to vasodilation, coronary blood flow enhancement, and anti-inflammatory pleiotropic effects beyond simple platelet inhibition.

Intracranial arteriosclerosis (ICAS) is driven by the same core pathophysiology as coronary artery disease: platelet-mediated thrombosis superimposed on atherosclerotic plaques within arterial walls, causing progressive luminal stenosis and downstream ischemia. Ticagrelor's dual mechanism applies directly: (1) P2Y12 antagonism suppresses platelet activation and aggregation in stenotic intracranial arteries; (2) adenosine accumulation via ENT-1 inhibition provides cerebrovascular anti-inflammatory protection and vasodilation, potentially reducing ischemic injury in patients who have experienced TIA or stroke from ICAS. Standard clopidogrel-based DAPT leaves a high residual 12-month recurrent stroke risk in symptomatic ICAS patients, making a more potent P2Y12 inhibitor a rational therapeutic step.

The mechanistic and clinical overlap is substantial enough that the field has progressed from hypothesis to active Phase 3 investigation. The ongoing CAPTIVA trial (NCT05047172, 1,683 patients) directly compares ticagrelor against clopidogrel and rivaroxaban for symptomatic ICAS — the strongest confirmation that this repurposing direction is well-founded. Complementary evidence from the EUCLID trial (PAD) and GLOBAL LEADERS (post-stent monotherapy) further establishes the safety and pharmacodynamic profile needed for this application.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT05047172	Phase 3	Active (Not Recruiting)	1,683	CAPTIVA trial: directly compares ticagrelor, rivaroxaban, and clopidogrel + aspirin for lowering the 1-year rate of ischemic stroke, ICH, or vascular death in symptomatic intracranial atherosclerotic stenosis — the most relevant and direct evidence for this indication
NCT01732822	Phase 3	Completed	13,885	EUCLID trial: compares ticagrelor vs clopidogrel in established peripheral artery disease for cardiovascular death, MI, and ischemic stroke; largest completed Phase 3 RCT providing direct ticagrelor safety/efficacy data in atherosclerotic vascular disease
NCT06714526	N/A	Recruiting	100	Pilot PROBE study: genotype-guided P2Y12 inhibitor selection (including ticagrelor) vs conventional clopidogrel in symptomatic intracranial atherosclerotic disease; directly addresses the ICAD patient population
NCT04948749	N/A	Recruiting	792	DREAM-PRIDE: randomized trial comparing drug-eluting stent implantation plus aggressive medical treatment (ticagrelor-based DAPT) vs medical treatment alone for preventing 1-year recurrent stroke in symptomatic intracranial atherosclerotic disease
NCT01813435	Phase 3	Completed	15,991	GLOBAL LEADERS: ticagrelor + aspirin for 1 month followed by ticagrelor monotherapy for 23 months vs standard 12-month DAPT post coronary stenting; largest safety database for long-term ticagrelor monotherapy
NCT02605447	Phase 4	Completed	2,009	EVOLVE Short DAPT: safety of 3-month DAPT in high bleeding risk patients post-PCI; provides safety reference data for abbreviated DAPT strategies relevant to neurointerventional contexts
NCT06058130	N/A	Unknown	2,171	Combination antiplatelet + anticoagulation in acute ischemic stroke patients with concomitant non-valvular atrial fibrillation and extracranial/intracranial artery stenosis; 1:1 randomized, 3-month composite endpoint
NCT07164859	Phase 3	Not Yet Recruiting	1,700	SOLOPCI: very short DAPT (aspirin stopped at day 7) followed by P2Y12 inhibitor monotherapy in elderly patients ≥65 years post-PCI; evaluates bleeding reduction without increasing cardiovascular events
NCT07354828	N/A	Not Yet Recruiting	3,500	Quality control standard system for coronary revascularization based on DAPT; addresses DAPT optimization and high-bleeding-risk management in real-world coronary practice
NCT03620760	Phase 4	Unknown	2,036	Randomized comparison of low-dose ticagrelor (45 mg BID) vs standard dose (90 mg BID) in Chinese patients with unstable angina post drug-eluting stent; dose optimization data applicable to Asian populations

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39862061	2025	RCT Protocol	International Journal of Stroke	CAPTIVA trial design and early progress: details the rationale for testing ticagrelor vs clopidogrel + aspirin in symptomatic ICAS; standard dual therapy leaves unacceptably high 12-month recurrent stroke risk, motivating the trial
38252758	2024	Guideline Update	Stroke	AHA/ASA focused update on intracranial atherosclerosis: summarizes current evidence gaps in antithrombotic management and identifies ongoing trials such as CAPTIVA as critical knowledge-gap closers for ICAS treatment
39658130	2025	Clinical Study	Journal of Neurointerventional Surgery	Real-world experience with lower-dose ticagrelor (60 mg BID) + aspirin 81 mg for intracranial stenting vs standard aspirin + clopidogrel; demonstrates feasibility, adequate platelet inhibition, and acceptable safety profile specifically in neurointerventional procedures

Italy Market Information

No authorized products for Ticagrelor are documented in this dataset (0 records retrieved). Authorization records for Italy were not available in the queried data source at the time of this report.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The CAPTIVA Phase 3 trial (NCT05047172) is actively investigating ticagrelor specifically in symptomatic intracranial atherosclerotic stenosis, and the broader P2Y12 inhibitor evidence base across atherosclerotic vascular disease (including multiple completed Phase 3 RCTs) provides an L1-level foundation. The TxGNN score of 99.97% combined with direct mechanistic plausibility and active clinical trial infrastructure supports moving forward — but critical data gaps in safety documentation must be resolved before any institutional protocol is designed.

To proceed, the following is needed:

Retrieve full MOA documentation from DrugBank (DB08816) to complete mechanistic and pharmacological analysis
Obtain the EU SmPC / prescribing information for Ticagrelor (Brilique®) to populate key warnings, contraindications, and clinically significant drug interactions
Monitor CAPTIVA trial results (projected completion: January 2027) — these data will determine whether this direction reaches definitive L1 ICAS-specific evidence
Confirm current Italy (AIFA) authorization status directly through official channels, as EMA approval of Brilique® for ACS is likely already in force
Define the target patient population precisely (e.g., symptomatic ICAS with ≥50% stenosis, TIA with atherosclerotic etiology) before designing any investigator-initiated or off-label use protocol
Assess bleeding risk profile in cerebrovascular patients, where intracranial hemorrhage is a particularly consequential adverse event
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.